Evaxion Biotech (EVAX) Gets a Buy from Lake Street
Lake Street analyst Thomas Flaten maintained a Buy rating on Evaxion Biotech (EVAX – Research Report) today and set a price target of $6.00.
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion ...
Daily Guide Ghana on MSN15h
Vivo Energy Unveils New Corporate Brand
Vivo Energy has launched a dynamic new corporate brand as a significant milestone to the growth of the company.The new corporate identity includes a bold new brand personality which is confident, ...